BMS 205820
Latest Information Update: 17 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart transplant rejection
Most Recent Events
- 30 Jun 1999 New profile
- 30 Jun 1999 Preclinical development for Heart transplant rejection in USA (Unknown route)